To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.
Age ≥18 years and ≤80 years.
Chest pain lasting >30 minutes, and
ST-segment elevation in at least two contiguous leads: ≥0.2 mV in leads V2-V3 (≥0.2 mV for men, ≥0.15 mV for women) or ≥0.1 mV in other leads, or new-onset left bundle branch block.
Reperfusion therapy: Symptom onset to first medical contact ≤12 hours, and successful primary PCI (culprit vessel opened, post-procedure TIMI flow grade 3).
Non-atherosclerotic MI: coronary embolism, spasm, aortic dissection, myocarditis, Takotsubo.
Prior HF (NYHA ≥II);
Severe CKD (eGFR <30 mL/min/1.73m² or dialysis);
Severe liver disease (Child-Pugh B/C);
Beijing Anzhen Hospital
Lead sponsor
Beijing Jishuitan Hospital
Collaborator
Institute of Biophysics, Chinese Academy of Sciences
Collaborator